Melqart Asset Management UK Ltd Takes Position in Grifols, S.A. (NASDAQ:GRFS)

Melqart Asset Management UK Ltd acquired a new position in shares of Grifols, S.A. (NASDAQ:GRFS) in the third quarter, Holdings Channel.com reports. The institutional investor acquired 183,351 shares of the biotechnology company’s stock, valued at approximately $1,628,000.

Other large investors also recently modified their holdings of the company. GAMMA Investing LLC grew its stake in shares of Grifols by 49.4% in the 3rd quarter. GAMMA Investing LLC now owns 3,432 shares of the biotechnology company’s stock worth $30,000 after acquiring an additional 1,135 shares in the last quarter. Signaturefd LLC grew its position in Grifols by 66.2% in the 3rd quarter. Signaturefd LLC now owns 5,407 shares of the biotechnology company’s stock worth $48,000 after purchasing an additional 2,153 shares in the last quarter. HighTower Advisors LLC increased its stake in Grifols by 12.5% in the 3rd quarter. HighTower Advisors LLC now owns 13,930 shares of the biotechnology company’s stock valued at $123,000 after buying an additional 1,546 shares during the last quarter. AQR Capital Management LLC bought a new position in shares of Grifols during the 2nd quarter worth approximately $89,000. Finally, Chesapeake Capital Corp IL purchased a new position in shares of Grifols in the 3rd quarter worth approximately $148,000.

Grifols Trading Up 1.4 %

Grifols stock opened at $7.23 on Wednesday. The company has a current ratio of 2.26, a quick ratio of 0.79 and a debt-to-equity ratio of 1.11. The business’s 50 day simple moving average is $8.73 and its 200 day simple moving average is $8.10. Grifols, S.A. has a 12 month low of $5.30 and a 12 month high of $12.15.

Analysts Set New Price Targets

Separately, Berenberg Bank raised Grifols to a “strong-buy” rating in a research report on Tuesday, October 29th.

Grifols Company Profile

Grifols, SA operates as a plasma therapeutic company in Spain, the United States, Canada, and internationally. The company provides immunoglobulin to treat immunodeficiencies; albumin used to restore circulatory volume and protein loss in pathophysiological conditions, such as liver cirrhosis, cardiocirculatory failure, trauma and severe burns; alpha-1 proteinase inhibitor, a plasma protein, used to treat a genetic disease known as alpha-1; factorVIII/von Willerbrand factor and factor IX, clotting factors for the treatment of hemophilia A and von Willebrand’s disease, as well as hemophilia B; antithrombin III to treat hereditary antithrombin deficiency; Fostamatinib, a spleen tyrosine kinase inhibitor; combination of fibrinogen and enzyme thrombin that acts as a biological sealant to control surgical bleeding; and plasma exchange with albumin used to treat Alzheimer’s disease.